ERVW-1 and myeloid sarcoma: Although no causal link between HERV expression and the development of MS has yet been established, the therapeutic antibody temelimab, specific to the HERV-W envelope protein, has been tested in relapsing-remitting MS (the phase 2b clinical studies CHANGE-MS and ANGEL-MS, ClinicalTrials.gov identifiers: NCT02782858 and NCT03239860, respectively) [19].